Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 86Kidney Neoplasms 25Neoplasms 24Breast Neoplasms 18Gastrointestinal Stromal Tumors 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Brain Neoplasms 7Pancreatic Neoplasms 6Lung Neoplasms 6Colorectal Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Solid Tumors 5Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Neuroendocrine Tumors 5Melanoma 5Glioblastoma 5Carcinoma 5Sarcoma 4Liver Neoplasms 4Esophageal Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Carcinoma, Hepatocellular 4Astrocytoma 4Adenoma, Islet Cell 4Thyroid Cancer, Papillary 3

Interventions

niraparib 1cabozantinib 1avelumab 1Sunitinib 1Paclitaxel 1Gemcitabine 1Everolimus 1Cisplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urothelial Cancer × Sunitinib × Clear all
NCT00821327 2016-10-25

Gemzar, Cisp, Sunitinib Urothelial Ca

US Oncology Research

Phase 2 Completed
36 enrolled 9 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡